文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

日本2011-2017年院内心搏骤停的发病率与结局:一项全国住院数据库研究

Incidence and outcomes of in-hospital cardiac arrest in Japan 2011-2017: a nationwide inpatient database study.
PubMed 文献 · J Intensive Care · 2022-03-03
一句话结论日本全国数据库显示院内心搏骤停发病率为每1000例住院5.1例,2011至2017年发病率下降而出院存活率由10.5%升至14.0%。

该观察性队列研究利用日本2011年4月至2018年3月覆盖1626家急性期医院、约占全国50%急性期床位的全国行政住院数据库,将住院期间接受胸外按压心肺复苏的心搏骤停患者定义为院内心搏骤停(IHCA)。在53,871,101例无院外心搏骤停的住院患者中,2,136,038例(4.0%)发生心搏骤停,其中274,664例(12.9%)至少接受一次心肺复苏而被判定为IHCA。IHCA发病率为每1000例住院5.1例,从2011年6.1例显著降至2017年4.6例(趋势P=0.033);IHCA占心搏骤停患者比例从2011年14.0%显著降至2017年12.2%(趋势P=0.006);总体出院存活率12.7%,从2011年10.5%显著升至2017年14.0%(趋势P<0.001)。

要点

  • IHCA发病率为每1000例住院5.1例,从2011年6.1例显著降至2017年4.6例(趋势P=0.033)。
  • IHCA占所有住院心搏骤停患者的12.9%,从2011年14.0%显著降至2017年12.2%(趋势P=0.006)。
  • IHCA总体出院存活率为12.7%,从2011年10.5%显著升至2017年14.0%(趋势P<0.001)。
  • 估计日本每年约87,000例IHCA。

适用人群与场景

  • 2011年4月至2018年3月日本1626家急性期医院住院患者,排除院外心搏骤停患者。

诊断标准与关键阈值

  • IHCA定义为住院期间至少接受一次心肺复苏(胸外按压)的心搏骤停患者。

研究设计与关键结果

  • 研究类型:观察性队列研究,使用覆盖日本约50%急性期床位的全国行政住院数据库。
  • 样本量:53,871,101例无院外心搏骤停的住院患者,来自1626家医院。
  • 心搏骤停发生率:2,136,038例(4.0%)发生心搏骤停。
  • IHCA例数:274,664例(12.9%)至少接受一次心肺复苏,被判定为IHCA;1,861,374例(87.1%)未接受心肺复苏。
  • IHCA发病率:每1000例住院5.1例,从2011年6.1例显著降至2017年4.6例(趋势P=0.033)。
  • 估计日本每年约87,000例IHCA。
  • IHCA占心搏骤停患者比例:12.9%,从2011年14.0%显著降至2017年12.2%(趋势P=0.006)。
  • 出院存活率:总体12.7%,从2011年10.5%显著升至2017年14.0%(趋势P<0.001)。

证据类型、等级与局限

  • 证据类型:观察性队列研究(全国行政住院数据库)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although numerous studies have investigated out-of-hospital cardiac arrest, few studies have been conducted on in-hospital cardiac arrest (IHCA). Knowledge of the nationwide epidemiology of IHCA in Japan, with its super-aging society, is important to understand the current situation of IHCA and to establish evidenced-based medicine in the future. The present study aimed to determine the incidence and outcomes of IHCA and their trends in Japan.

METHODS: This observational cohort study was performed using a national administrative inpatient database for more than 1600 acute-care hospitals covering about 50% of all acute-care hospital beds in Japan from April 2011 to March 2018. We defined cardiac arrest patients who received cardiopulmonary resuscitation (chest compression) during hospitalization as IHCA. We excluded out-of-hospital cardiac arrest patients from the source population. The incidence of IHCA per 1000 hospital admissions and survival to discharge rate was reported with trend analyses by calendar year 2011-2017.

RESULTS: Among 53,871,101 hospitalized patients without out-of-hospital cardiac arrest patients in 1626 hospitals, 2,136,038 (4.0%) had cardiac arrest. Of them, 274,664 (12.9%) received cardiopulmonary resuscitation at least once during hospitalization and were identified as IHCA, and 1,861,374 (87.1%) did not receive cardiopulmonary resuscitation. The incidence of IHCA per 1000 hospital admissions was 5.1, with a significant decreasing trend from 6.1 in 2011 to 4.6 in 2017 (P for trend = 0.033). Our estimated incidence can be translated to approximately 87,000 IHCA cases in Japan each year. The percentage of IHCA patients among cardiac arrest patients was 12.9%, with a significant decreasing trend from 14.0% in 2011 to 12.2% in 2017 (P for trend = 0.006). The overall rate of survival to discharge was 12.7%, with a significant increasing trend from 10.5% in 2011 to 14.0% in 2017 (P for trend < 0.001).

CONCLUSIONS: We found substantial associations between mortality and loss of health and IHCA in Japan. The incidence of IHCA showed a decreasing trend over time, the percentage of treated cardiac arrest patients also had a decreasing trend, and the overall survival to discharge rate improved over time.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Ohbe H, Tagami T, Uda K, et al. Incidence and outcomes of in-hospital cardiac arrest in Japan 2011-2017: a nationwide inpatient database study. J Intensive Care. 2022. PMID: 35241166. doi:10.1186/s40560-022-00601-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。